Laroxyl

Amitriptyline, the active ingredient in Laroxyl, is a tricyclic antidepressant presented as a tablet for oral use. It is approved in the European Union for prescription‑only treatment of major depressive disorder, neuropathic pain, migraine prophylaxis and certain anxiety disorders in adult patients.

GNH USA supplies Laroxyl as a licensed, GDP‑compliant product, providing reliable international sourcing for hospitals, pharmacies and clinics worldwide. The company follows stringent quality‑assurance procedures and offers regulatory support to facilitate import and distribution across multiple markets in the healthcare sector.

Laroxyl (amitriptyline) acts on monoamine neurotransmitter pathways and is used for several psychiatric and pain‑related conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Neuropathic pain: alleviates chronic pain associated with diabetic neuropathy or post‑herpetic neuralgia. - Migraine prophylaxis: decreases frequency and severity of migraine attacks when taken regularly. - Anxiety disorders: helps control generalized anxiety symptoms and associated tension.

Amitriptyline may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dry mouth: reduced salivation leading to discomfort. - Drowsiness: increased sedation, especially after dose initiation. - Constipation: slowed gastrointestinal motility. - Weight gain: gradual increase in body weight over treatment. Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, particularly in patients with pre‑existing heart disease. - Seizures: risk of convulsions, especially at high doses or in susceptible individuals. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting.

When prescribing amitriptyline, clinicians should observe several safety considerations. - Assess cardiac history: evaluate for conduction abnormalities before initiating therapy. - Monitor for suicidal ideation: especially during the first weeks of treatment. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal symptoms. - Use caution in elderly: increased sensitivity to anticholinergic and sedative effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Amitriptyline can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs): combined therapy increases risk of serotonin toxicity. - Other tricyclic antidepressants: additive cardiotoxic effects and overdose risk. Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may raise amitriptyline plasma levels. - Anticholinergic drugs: combined use can enhance dry mouth, constipation, and urinary retention. - CNS depressants (e.g., alcohol, benzodiazepines): may intensify sedation and impair psychomotor performance.